Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8003673 | CUBIST PHARMS LLC | Daptomycin for the treatment of biofilm and catheter salvage |
Sep, 2028
(5 years from now) | |
US9138456 | CUBIST PHARMS LLC | Lipopeptide compositions and related methods |
Nov, 2030
(7 years from now) |
Market Authorisation Date: 12 September, 2003
Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis
Dosage: POWDER;INTRAVENOUS
9
United States
4
Japan
3
China
2
Peru
2
Taiwan, Province of China
2
Canada
2
Chile
2
European Union
1
Portugal
1
Turkey
1
Singapore
1
Russia
1
Spain
1
Brazil
1
Croatia
1
Costa Rica
1
Colombia
1
New Zealand
1
Dominican Republic
1
Argentina
1
Mexico
1
Lithuania
1
Cyprus
1
Hungary
1
Slovenia
1
Israel
1
Poland
1
Australia
1
Ecuador
1
RS
1
Denmark
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10357535 | HOSPIRA INC | Daptomycin formulations and uses thereof |
Sep, 2033
(10 years from now) | |
US9655946 | HOSPIRA INC | Daptomycin formulations and uses thereof |
Sep, 2033
(10 years from now) |
Market Authorisation Date: 21 June, 2021
Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administering the formulation as recited in claim 12; Treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by administering the formulation of daptomycin as recited in claim 18
Dosage: POWDER;INTRAVENOUS
7
United States
3
New Zealand
2
Australia
2
European Union
1
Germany
1
Singapore
1
Spain
1
Brazil
1
IB
1
Mexico
1
Morocco
1
Hong Kong
1
Tunisia
1
South Africa
1
Canada
1
Hungary
1
Saudi Arabia
1
Israel
1
Chile
1
Denmark
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11173189 | BAXTER HLTHCARE CORP | Daptomycin formulations containing a combination of sorbitol and mannitol |
Mar, 2041
(17 years from now) |
Market Authorisation Date: 25 January, 2022
Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol
Dosage: POWDER;INTRAVENOUS
5
United States
1
Australia
1
Canada
1
China
1
Brazil
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic